Metallopeptide-promoted inactivation of angiotensin-converting enzyme and endothelin-converting enzyme 1: Toward dual-action therapeutics.
A series of metallopeptides based on the amino terminal copper/nickel (ATCUN) binding motif have been evaluated as classical inhibitors and catalytic inactivators of both rabbit and human angiotensin-converting enzyme (hACE), and human endothelin-converting enzyme 1 (hECE-1). The cobalt complex [KGHK-Co(NH3)2]2+, where KGHK is lysylglycylhistidyllysine, displayed similar K(I) and IC50 values to those found for [KGHK-Cu]+, in spite of the enhanced charge, and so either the influence of charge is offset by the steric influence of the axially coordinated ammine ligands, or binding is dominated by contributions from the amino acid side chains, especially the C-terminal lysine that mimics the binding pattern observed for lisinopril. Moreover, the inhibition observed for [KGHK-Co(NH3)2]2+ contrasts with the activation of hACE by Co2+(aq), reflecting the stimulation of enzyme activity following replacement of the catalytic zinc cofactor by cobalt ion at each of the two active sites. Quantitative analysis of the dose-dependent stimulation of activity by Co2+(aq) yielded apparent affinities of 1.3 +/- 0.2 and 56 +/- 8 microM for the two sites in the presence of saturating Zn2+ (10 microM). Catalytic inactivation of hACE by [KGHK-Cu]+ at subsaturating concentrations had previously been characterized, with k(obs) = 2.9 +/- 0.5 x 10(-2) min(-1). Under similar conditions, the same complex is found to catalytically inactivate hECE-1, with k(obs) = 2.12 +/- 0.16 x 10(-2) min(-1), demonstrating the potential for dual-action activity against two key drug targets in cardiovascular disease. Irreversible inactivation of a drug target represents a novel mechanism of drug action that complements existing classical inhibitor strategies that underlie current drug discovery efforts.
Gokhale
Nikhil H
NH
Evans Laboratory of Chemistry, Ohio State University, 100 West 18th Avenue, Columbus, OH 43210, USA.
Cowan
J A
JA
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology; D000818:Animals; D016282:Aspartic Acid Endopeptidases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D002478:Cells, Cultured; D003035:Cobalt / Q000737:chemistry; D003300:Copper / Q000737:chemistry; D004305:Dose-Response Relationship, Drug; D015536:Down-Regulation; D015195:Drug Design; D000072396:Endothelin-Converting Enzymes; D006801:Humans; D008168:Lung / Q000166:cytology / Q000201:enzymology; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015394:Molecular Structure; D009532:Nickel / Q000737:chemistry; D009942:Organometallic Compounds / Q000737:chemistry* / Q000494:pharmacology; D010084:Oxidation-Reduction; D010455:Peptides / Q000737:chemistry* / Q000494:pharmacology; D007703:Peptidyl-Dipeptidase A / Q000187:drug effects / Q000378:metabolism*; D011817:Rabbits; D011994:Recombinant Proteins / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism
D000806:Angiotensin-Converting Enzyme Inhibitors; D009942:Organometallic Compounds; D010455:Peptides; D011994:Recombinant Proteins; D003035:Cobalt; D003300:Copper; D009532:Nickel; D007703:Peptidyl-Dipeptidase A; D016282:Aspartic Acid Endopeptidases; D008666:Metalloendopeptidases; C000606923:ECE1 protein, human; D000072396:Endothelin-Converting Enzymes